Table 1 Summary of BsAbs in development for MM.
BsAb | Target | Development stage | Ongoing studies | ||
|---|---|---|---|---|---|
Study | Monotherapy or combination | Patient population | |||
Teclistamab | BCMA x CD3 | EMA approved for adult RRMM who have received at least three prior lines of therapy (including an IMiD, PI, and anti-CD38 antibody) [5] FDA approved for adult RRMM patients who have received four prior lines of therapy (including a PI, IMiD, and anti-CD38 monoclonal antibody) [6] | MajesTEC-1 (NCT04557098) [24] | Monotherapy | RRMM |
MajesTEC-2 (NCT04722146) [77] | Combination with anti-cancer therapies | MM | |||
MajesTEC-3 (NCT05083169) [78] | Combination with daratumumab | RRMM | |||
MajestTEC-4 (NCT05243797) [79] | Combination with lenalidomide | NDMM (as post-ASCT maintenance) | |||
MajestTEC-7 (NCT05552222) [80] | Combination with daratumumab and lenalidomide | NDMM who are transplant ineligible or not intended for ASCT | |||
MajesTEC-9 (NCT05572515) [81] | Monotherapy | RRMM | |||
NCT04696809 [82] | Monotherapy | RRMM | |||
IFM 2021-01 (NCT5572229) [83] | Combination with daratumumab or lenalidomide | MM (elderly patients) | |||
RedirecTT-1 (NCT04586426) [84] | Combination with talquetamab | RRMM | |||
TRIMM-3 (NCT05338775) [85] | Teclistamab or talquetamab in combination with PD-1 inhibitor | RRMM | |||
ImmunoPRISM (NCT05469893) [86] | Monotherapy | Smoldering MM | |||
MASTER-2 (NCT05231629) [87] | Combination with daratumumab | NDMM | |||
NCT04108195 [88] | Teclistamab/talquetamab combination with daratumumab and/or pomalidomide | MM | |||
Elranatamab | BCMA x CD3 | Phase III | MagnetisMM-1 (NCT03269136) [89] | Monotherapy or in combination with lenalidomide or pomalidomide | RRMM |
MagnetisMM-2 (NCT04798586) [90] | Monotherapy | RRMM | |||
MagnetisMM-3 (NCT04649359) [91] | Monotherapy | RRMM | |||
MagnetisMM-4 (NCT05090566) [92] | Combination with either nirogacestat or lenalidomide + dexamethasone | RRMM | |||
MagnetisMM-5 (NCT05020236) [93] | Monotherapy and in combination with anti-cancer therapies | RRMM | |||
MagnetisMM-6 (NCT05623020) [94] | Combination with daratumumab, lenalidomide and dexamethasone | NDMM | |||
MagnetisMM-7 (NCT05317416) [95] | Monotherapy | NDMM | |||
MagnestisMM-8 (NCT05228470) [96] | Monotherapy | RRMM | |||
MagnestisMM-9 (NCT05014412) [97] | Monotherapy | RRMM | |||
REGN5458 | BCMA x CD3 | Phase I/II | LINKER-MM1 (NCT03761108) [98] | Monotherapy | RRMM |
NCT05137054 [98] | Combination with anti-cancer therapies | RRMM | |||
ABBV-383 | BCMA x CD3 | Phase I/II | NCT03933735 [20] | Monotherapy | RRMM |
Pavurutamab | BCMA x CD3 | Phase I | ParadigMM-1B (NCT03287908) [99] | Monotherapy and combination with pomalidomide with/without dexamethasone | RRMM |
Alnuctamab | BCMA x CD3 | Phase I | NCT03486067 [34] | Monotherapy | RRMM |
WVT078 | BCMA x CD3 | Phase I | NCT04123418 [100] | Monotherapy and in combination with WHG626 | MM |
Talquetamab* | GPRC5D x CD3 | Phase III | MonumenTAL-1 (NCT03399799) [30] | Monotherapy | RRMM |
MonumenTAL-2 (NCT05050097) [101] | Combination with anticancer therapies | RRMM | |||
MonumenTAL-3 (NCT05455320) [102] | Combination with daratumumab with/without pomalidomide | RRMM | |||
MonumenTAL-5 (NCT05461209) [103] | Monotherapy | RRMM | |||
NCT04654552 [104] | Monotherapy | RRMM | |||
NCT04773522 [105] | Monotherapy | RRMM | |||
RG6234 | GPRC5D x CD3 | Phase I | NCT04557150 [35] | Monotherapy | RRMM |
Cevostamab | FcRH5 x CD3 | Phase I/II | CAMMA 1 (NCT04910568) [106] | Monotherapy and combination with pomalidomide/daratumumab and dexamethasone | RRMM |
CAMMA 2 (NCT05535244) [107] | Monotherapy | BCMA-exposed RRMM | |||
PLYCOM (NCT05583617) [108] | Combination with tocilizumab and lenalidomide | MM | |||
NCT03275103 [10] | Monotherapy | RRMM | |||
ISB 1342 | CD38 x CD3 | Phase I | NCT03309111 [109] | Monotherapy | Previously treated MM |
